This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
by Zacks Equity Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
by Zacks Equity Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
by Zacks Equity Research
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Company News for Sep 20, 2022
by Zacks Equity Research
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal
by Zacks Equity Research
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
GSK (GSK) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.02, moving -0.58% from the previous trading session.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
by Zacks Equity Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $31.51, marking a +0.06% move from the previous day.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
by Zacks Equity Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
by Zacks Equity Research
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
by Zacks Equity Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $31.85 in the latest trading session, marking a +0.5% move from the prior day.
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
by Zacks Equity Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
by Zacks Equity Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
by Zacks Equity Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).